Deciphex, a Dublin-based company offering digital pathology solutions, announced a €15 million debt facility from Claret Capital Partners. The funding follows a €31 million Series C round in January as Deciphex works to become the leading histopathology reporting provider in the U.K.
The company’s technology leverages AI to automate routine tasks for pathologists. Its Diagnexia product connects global subspecialty pathologists to enable quicker diagnostics and backlog reduction, and its Patholytix tool expedites drug development by optimizing preclinical safety assessments. Deciphex’s reach spans regions across Europe, North America and East Asia, and it manages over 250 subspecialty pathologists and processes about 97,000 cases a year.
Backed by its new funding, Deciphex will scale its solutions for clinical diagnostics and pharmaceutical research and build out its presence within the U.S and U.K. markets.
